HIA
KYMR icon

HFM Investment Advisors’s Kymera Therapeutics KYMR Stock Holding History

HFM Investment Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$167 Hold
2
– – ﹤0.01% 1036
2025
Q4 		$156 Buy
2
+1
+100% +$68 ﹤0.01% 1091
2025
Q3 		$57 Buy
+1
New +$45 ﹤0.01% 1209

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

HFM Investment Advisors's KYMR Position: Q1 2026 in Review

HFM Investment Advisors held its Kymera Therapeutics (KYMR) position steady in Q1 2026 at 2 shares worth $167. The position accounts for ﹤0.01% of the portfolio, ranked #1036.

HFM Investment Advisors first reported a position in KYMR in Q3 2025 and has held it in 3 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • HFM Investment Advisors held 2 shares of Kymera Therapeutics worth $167 as of Q1 2026.
  • HFM Investment Advisors left its Kymera Therapeutics share count unchanged in Q1 2026.
  • Kymera Therapeutics made up ﹤0.01% of HFM Investment Advisors's portfolio in Q1 2026, its #1036 holding.
  • HFM Investment Advisors first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on HFM Investment Advisors's 13F filing for Q1 2026, filed 1 May 2026.